Neuphoria Therapeutics Inc(NEUP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NEUP Neuphoria Therapeutics Inc

未开盘 12-09 16:00:00 EST

4.60

+0.06

+1.32%

盘后4.59

-0.01-0.22%

19:24 EST

最高4.65	最低4.37	成交量7.40万
今开4.45	昨收4.54	日振幅6.17%
总市值2,474万	流通市值1,779万	总股本537.73万
成交额33.69万	换手率1.91%	流通股本386.78万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NEUP","market":"US","secType":"STK","nameCN":"Neuphoria Therapeutics Inc","latestPrice":4.6,"timestamp":1765314000000,"preClose":4.54,"halted":0,"volume":73950,"hourTrading":{"tag":"盘后","latestPrice":4.59,"preClose":4.6,"latestTime":"19:24 EST","volume":7272,"amount":33427.3454,"timestamp":1765326241554},"delay":0,"floatShares":3867799,"shares":5377329,"eps":-5.092314,"marketStatus":"未开盘","change":0.06,"latestTime":"12-09 16:00:00 EST","open":4.45,"high":4.65,"low":4.37,"amount":336907.62179999996,"amplitude":0.061674,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.092314,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765357200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":4.54,"preHourTrading":{"tag":"盘前","latestPrice":4.3377,"preClose":4.54,"latestTime":"08:43 EST","volume":1744,"amount":7703.8280544,"timestamp":1765287828110},"postHourTrading":{"tag":"盘后","latestPrice":4.59,"preClose":4.6,"latestTime":"19:24 EST","volume":7272,"amount":33427.3454,"timestamp":1765326241554},"volumeRatio":1.065795},"requestUrl":"/m/hq/s/NEUP","defaultTab":"news","newsList":[{"id":"1178607496","title":"Neuphoria Therapeutics Inc - 敦促股东在白色代理卡上投票支持Neuphoria的两名提名人","url":"https://stock-news.laohu8.com/highlight/detail?id=1178607496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178607496?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:05","pubTimestamp":1764853516,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc - 敦促股东在白色代理卡上投票支持Neuphoria的两名提名人","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"1164604292","title":"Neuphoria Therapeutics Inc - 暂停Bnc210在创伤后应激障碍方面的研发支出，并在公司战略评估中评估所有可能性","url":"https://stock-news.laohu8.com/highlight/detail?id=1164604292","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164604292?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:03","pubTimestamp":1764853402,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc - 暂停Bnc210在创伤后应激障碍方面的研发支出，并在公司战略评估中评估所有可能性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"1127135911","title":"Lynx1 Capital Management向Neuphoria Therapeutics提出非约束性收购提议，报价为每股4.75美元现金","url":"https://stock-news.laohu8.com/highlight/detail?id=1127135911","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127135911?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:35","pubTimestamp":1764682510,"startTime":"0","endTime":"0","summary":"Lynx1 Capital Management向Neuphoria Therapeutics提出非约束性提议，计划以每股4.75美元的现金收购其所有流通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"1188165374","title":"Lynx1 Capital Management Lp 于12月2日向Neuphoria Therapeutics董事会提交函件 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1188165374","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188165374?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:32","pubTimestamp":1764682337,"startTime":"0","endTime":"0","summary":"Lynx1 Capital Management Lp 于12月2日向Neuphoria Therapeutics董事会提交函件 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"1125692194","title":"Lynx1 Capital Management Lp撤回收购Neuphoria Therapeutics的非约束性提议 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1125692194","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125692194?lang=zh_cn&edition=full","pubTime":"2025-11-18 21:38","pubTimestamp":1763473129,"startTime":"0","endTime":"0","summary":"Lynx1 Capital Management Lp撤回了此前提出的收购Neuphoria Therapeutics的非约束性提议，并已在SEC备案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"1138335047","title":"Neuphoria Therapeutics Inc - 可能不定期提供和销售高达2000万美元的普通股 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1138335047","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138335047?lang=zh_cn&edition=full","pubTime":"2025-11-15 05:25","pubTimestamp":1763155509,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc - 可能不定期提供和销售高达2000万美元的普通股 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"1143200172","title":"Neuphoria Therapeutics Inc - Lynx1 Master Fund在11月10日提供每股5.20美元现金收购Neuphoria","url":"https://stock-news.laohu8.com/highlight/detail?id=1143200172","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143200172?lang=zh_cn&edition=full","pubTime":"2025-11-11 20:02","pubTimestamp":1762862533,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc - Lynx1 Master Fund在11月10日提供每股5.20美元现金收购Neuphoria","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"1162850350","title":"Neuphoria Therapeutics：确认收到Lynx1 Master Fund Lp的非正式投资意向及董事提名","url":"https://stock-news.laohu8.com/highlight/detail?id=1162850350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162850350?lang=zh_cn&edition=full","pubTime":"2025-11-11 20:01","pubTimestamp":1762862483,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics：确认收到Lynx1 Master Fund Lp的非正式投资意向及董事提名","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"1154437346","title":"Neuphoria Therapeutics Inc - 董事会宣布每股发行一项优先股购买权的股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1154437346","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154437346?lang=zh_cn&edition=full","pubTime":"2025-10-28 04:30","pubTimestamp":1761597014,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc - 董事会宣布每股发行一项优先股购买权的股息","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"1105322519","title":"Neuphoria Therapeutics通过有限期限股东权利计划以保护过程的完整性","url":"https://stock-news.laohu8.com/highlight/detail?id=1105322519","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105322519?lang=zh_cn&edition=full","pubTime":"2025-10-28 04:30","pubTimestamp":1761597014,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics通过有限期限股东权利计划以保护过程的完整性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"1151086403","title":"Neuphoria Therapeutics：可能不时提供和出售高达2190万美元的普通股 - SEC 备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1151086403","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151086403?lang=zh_cn&edition=full","pubTime":"2025-10-27 21:45","pubTimestamp":1761572715,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics：可能不时提供和出售高达2190万美元的普通股 - SEC 备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"1137881661","title":"Neuphoria股价因试验失败暂停焦虑药物项目下跌65.8%至5.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137881661","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137881661?lang=zh_cn&edition=full","pubTime":"2025-10-21 16:29","pubTimestamp":1761035350,"startTime":"0","endTime":"0","summary":"Neuphoria股价因试验失败导致焦虑药物项目暂停，盘前下跌65.8%，报5.27美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"1179026626","title":"Neuphoria Therapeutics 股价在延长交易中下跌67.21%，报5.05美元；在第三阶段试验后停止焦虑药物的开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1179026626","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179026626?lang=zh_cn&edition=full","pubTime":"2025-10-21 05:39","pubTimestamp":1760996350,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics 股价在延长交易中下跌67.21%，报5.05美元；在第三阶段试验后停止焦虑药物的开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"1102819182","title":"Neuphoria Therapeutics更新Affirm-1三期试验进展，评估Bnc210治疗社交焦虑症急性发作","url":"https://stock-news.laohu8.com/highlight/detail?id=1102819182","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102819182?lang=zh_cn&edition=full","pubTime":"2025-10-21 04:16","pubTimestamp":1760991368,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics更新Affirm-1三期试验进展，评估Bnc210治疗社交焦虑症急性发作","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"1192631265","title":"Neuphoria Therapeutics Inc在SAD治疗药物BNC-210的AFFIRM-1 III期试验中达成LPLV里程碑，预计第四季度公布顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1192631265","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192631265?lang=zh_cn&edition=full","pubTime":"2025-09-30 04:57","pubTimestamp":1759179434,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc在其BNC-210治疗季节性情感障碍(SAD)的AFFIRM-1 III期试验中成功达成LPLV里程碑，预计将在第四季度公布顶线研究结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"1142513631","title":"Neuphoria Therapeutics完成Bnc-210治疗社交焦虑症3期Affirm-1试验的目标入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1142513631","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142513631?lang=zh_cn&edition=full","pubTime":"2025-09-04 19:00","pubTimestamp":1756983626,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics已完成其针对社交焦虑症(SAD)的药物Bnc-210的3期Affirm-1临床试验目标入组工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neuphoriatx.com","stockEarnings":[{"period":"1week","weight":0.0526},{"period":"1month","weight":0.122},{"period":"3month","weight":-0.6695},{"period":"6month","weight":-0.3557},{"period":"1year","weight":0.5146},{"period":"ytd","weight":0.3411}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.1313},{"period":"1year","weight":0.1296},{"period":"ytd","weight":0.1654}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neuphoria Therapeutics Inc.（原名Bionomics Limited）于1996年根据澳大利亚法律注册成立，并于2024年12月24日迁移至特拉华州并成为国内公司。作为一家临床阶段的生物技术公司，它开发神经精神障碍疗法。其主要候选药物BNC210（口服选择性α 7烟碱性ACH受体调节剂）针对急性SAD和慢性PTSD，超过2700万美国患者的需求未得到满足。BNC210是一种首创的抗焦虑疗法，可在没有镇静、认知问题或成瘾的情况下快速恢复神经递质平衡。它与默沙东（美国/加拿大以外）就两种早期临床CNS药物建立了合作伙伴关系。其管线包括下一代α 7受体和KV3.1/3.2临床前项目（先导优化）。目前的治疗方法（抗抑郁药、苯二氮卓类药物）几十年来缺乏FDA的新批准，存在缺陷；BNC210在试验中显示出快速的作用和没有限制性副作用。","exchange":"NASDAQ","name":"Neuphoria Therapeutics Inc","nameEN":"Neuphoria Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neuphoria Therapeutics Inc(NEUP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Neuphoria Therapeutics Inc(NEUP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Neuphoria Therapeutics Inc,NEUP,Neuphoria Therapeutics Inc股票,Neuphoria Therapeutics Inc股票老虎,Neuphoria Therapeutics Inc股票老虎国际,Neuphoria Therapeutics Inc行情,Neuphoria Therapeutics Inc股票行情,Neuphoria Therapeutics Inc股价,Neuphoria Therapeutics Inc股市,Neuphoria Therapeutics Inc股票价格,Neuphoria Therapeutics Inc股票交易,Neuphoria Therapeutics Inc股票购买,Neuphoria Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neuphoria Therapeutics Inc(NEUP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Neuphoria Therapeutics Inc(NEUP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}